Healthcare
Ocugen, Inc.(OCGN)
Live Price
Offline$1.24
+0.81% today
1Y Change
+26.02%
Window
Jun 27, 2025 โ Jun 18, 2026
- Market Cap
- $590.00M
- Revenue Growth
- +8.8%
- EPS Growth
- -15.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 27, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ocugen, Inc. (OCGN) is a Healthcare stock with a market cap of $590.00M and listed on NASDAQ. The stock last traded around $1.24 and up 26.0% across the available one-year price window (Jun 27, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +8.8%, EPS growth of -15.0%, a dividend yield of 0.0%. What stands out right now is revenue +8.8%, EPS -15.0%, free cash flow -25.5% with operating margin -1425.7% and ROIC -269.4%. Valuation already assumes a fairly strong business story at price/sales 133.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OCGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.8% vs +7.6% peer median
Operating Margin
Below sector median
-1425.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +8.8% and EPS is at -15.0%, with operating margin around -1425.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | -2.0% | -7.9% | -16.6% |
2026 Mar 4, 2026 | +0.0% | -11.2% | +17.3% | -8.7% |
2025 Nov 5, 2025 | -21.7% | -2.1% | -5.0% | -12.1% |
Benchmark Edge
OCGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OCGN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OCGN Max Drawdown
-52.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OCGN and SPY.
Company Overview
Ocugen, Inc.
NASDAQ Capital Market
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
- Leadership
- Shankar Musunuri
- IPO Date
- Dec 3, 2014
- Employees
- 95
- Street Address
- 263 Great Valley Parkway
- Mailing
- Malvern, PA, 19355
- Region
- Malvern, PA, US
- Reporting Currency
- USD
- Investor Line
- 484 328 4701
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 133.7
- Price/Book
- โ
Growth
- Revenue
- +8.8%
- EPS
- -15.0%
- Free Cash Flow
- -25.5%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -1425.7%
- Net Margin
- -1537.4%
- ROE
- -2626.4%
- ROIC
- -269.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.